Navigation Links
Venaxis to Present at Canaccord Genuity 34th Annual Growth Conference
Date:8/6/2014

CASTLE ROCK, Colo., Aug. 5, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™ Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, today announced it will present at the Canaccord Genuity 34th Annual Growth Conference, to be held August 13-14, 2014, at the Intercontinental Boston in Boston, MA.

Steve Lundy, President and CEO of Venaxis, will provide an overview of the Company's business during his scheduled presentation and will be available for one-on-one meetings with investors who are registered to attend the conference. 

Event: Canaccord Genuity 34th Annual Growth Conference

Date: Thursday, August 14, 2014

Presentation Time: 1:00 pm (Eastern Time)

Location: Melbourne Room

The presentation will be webcast live.  To access the webcast, please visit the investor relations section of the Venaxis website at http://ir.venaxis.com

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, multi-analyte assay for appendicitis.  This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference
2. Venaxis APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
3. Venaxis Announces Pricing of Offering of Common Stock and Warrants
4. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
5. Ardelyx to Present at the Wedbush 2014 Life Sciences Management Access Conference
6. Intrexon to Present at Jefferies 2014 Global Industrials Conference
7. Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference
8. TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner
9. Dmitry Medvedev Presented BIOCAD the First National "Industry" Award
10. Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness"
11. Neuralstem President And CEO To Present 2014 Trials Overview At 2014 Biotech Showcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Proove Biosciences, a commercial ... relationship of genetics and hypertension at the International Academy of Cardiology ... Columbia, Canada. The event, which boasts an extensive overview of the latest research ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a global biotech ... manufacture of highly valued cardiac markers used in early detection of heart disease ... chemistry has led to the development and commercialization of important cardiac biomarkers used ...
(Date:8/26/2015)... , August 26, 2015 Israel Proves Its ... wins 1 st place  Wayerz comes in 5 ... Israel by venture capital fund JVP, with Chinese ... US, China , Israel , ... .  Impressive achievement for the Israeli representatives in the ...
(Date:8/26/2015)... ... 2015 , ... PRC Clinical, a Clinical Trial Management Expert CRO, ... in southern California. The Clinical Trial Management Expert CRO seeks to introduce more California-based ... , Stem Cell Meeting on the Mesa on October ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... 24 /PRNewswire-Asia-FirstCall/ --, -- Q4 FY 2009 Revenues increased 43.2% ... to $2.2 Million with diluted EPS of $0.08, -- FY ... Increased 32.4% to $7.9 Million vs. FY08 with diluted EPS ... 124.8% to $8.3 Million, -- June 30, 2009 Cash and ...
... , , , ABBOTT PARK, ... third-quarter 2009 financial results on Wednesday, Oct. 14, 2009, before the market opens. ... a live webcast of the earnings conference call at 8 a.m. Central time ... at www.abbottinvestor.com. An archived edition of the call will be available after ...
... ... completed a $25 million round of funding. Participating investors included CTTV Investments LLC, ... Lightspeed Venture Partners. , ... South San Francisco, CA (PRWEB) September 24, 2009 -- LS9, Inc., the Renewable ...
Cached Biology Technology:Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 2Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 3Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 4Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 5Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 6Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 7Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 8Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 9Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 10Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 11Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 12LS9 Secures $25 Million in Latest Round of Funding 2LS9 Secures $25 Million in Latest Round of Funding 3
(Date:8/5/2015)... According to a new market research report, ... (BFSI, Airport, IT & Telecom, Utilities, Education, Defense & ... published by MarketsandMarkets, defines and segments the Physical Identity ... global PIAM Market is estimated to grow from $272.2 ... a CAGR of 14.9 % from 2014 to 2019. ...
(Date:8/4/2015)... (NASDAQ: AMRI ) today reported financial and operating results for ... , Second quarter contract revenue of $ 85.2 ... Adjusted contract margins of 26 % , ... in EPS from royalties in the current quarter , ... are very pleased to present another strong financial quarter, with all ...
(Date:7/31/2015)... 2015 A 10 a. Conferência Internacional ... BGI de 22-25 de outubro de 2015, em ... está celebrando seu 10 o. aniversário este ano. Desde ... das reuniões mais influentes do mundo no ramo das ... e prazerosos. A ICG-10 se concentra ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... The University of Utah is launching a six-year, $21.5 ... materials for uses ranging from faster computers and communications devices ... Center of Excellence in Materials Research and Innovation is being ... grant from the National Science Foundation (NSF), $6.5 million for ...
... reversible adhesives; tenaciously clinging barnacles; and surfaces that rub ... topics that will be presented at the AVS 58th ... place Oct. 30 - Nov. 4, 2011, at the ... press registration to journalists; see details below. Journalists may ...
... Three leading sci-tech experts described engineering trends for ... this summer at the Directors Guild in Los ... of Sciences (NAS) Science & Entertainment Exchange to ... and scientists that engage the public in television, ...
Cached Biology News:$21.5 million for materials research at the University of Utah 2$21.5 million for materials research at the University of Utah 3Media invited: AVS 58th International Symposium and Exhibition 2Media invited: AVS 58th International Symposium and Exhibition 3Media invited: AVS 58th International Symposium and Exhibition 4Media invited: AVS 58th International Symposium and Exhibition 5IEEE-USA/NAS Hollywood Forum describes engineering trends for entertainment industry professionals 2
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
... The JNK (c-Jun NH2-terminal kinase) signal ... identified MAP kinase pathways in mammals. ... to environmental stress, is associated with ... and is implicated in the immune ...
... is an automated, two-dimensional fractionation system for ... Part of Beckman Coulters ProteomeLab family of ... just hours. The system effectively resolves ... lysates, addressing a key challenge in todays ...
... The ProteomeLab PA 800 is ... Part of Beckman Coulters ProteomeLab ... offers a comprehensive range of automated ... determination, peptide mapping, isoelectric focusing, carbohydrate ...
Biology Products: